Skip to main content
    D

    Dare Bioscience Inc (DARE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.58
    -0.07 (-11.13%)

    Market Cap: $12.93M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Dare Bioscience Inc (DARE) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Dare Bioscience (DARE) trades at 6.4x sales. Its forward P/E is 1.3x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E1.3x
    Price to sales6.4x
    EV/FCF0.3x
    PEGN/A
    FCF yield-135.1%
    As of Nov 17, 2026

    Valuation History

    Over the 6 of the 10 year ends shown that have a P/B, its P/B ranged from 2.7x in 2021 to 33.6x in 2019.

    Year endPriceP/SP/B
    2025$1.9328.2x9.8x
    2024$3.12N/AN/A
    2023$3.719.8xN/A
    2022$9.96N/A6.1x
    2021$24.01N/A2.7x
    2020$16.09N/AN/A
    2019$9.84N/A33.6x
    2018$8.53N/A14.5x
    2017$25.98N/A5.8x
    2016$85.02N/AN/A
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About DARE

    What is DARE's forward P/E ratio?

    Dare Bioscience has a forward P/E ratio of 1.3x.

    Is DARE stock overvalued?

    GNG's valuation label for DARE is Undervalued.

    What is DARE's price to sales ratio?

    Dare Bioscience has a price to sales ratio of 6.4x.